Daily brief
An FDA decision and a Nepal hospital proposal
The November 16 briefing separates a US drug-application decision from Chinese approvals and reports a request for support in Nepal.
By Medical2China · Video date
Three things to know
The video reports that the US FDA declined to approve Summit’s ivonescimab plus chemotherapy for previously treated, EGFR-mutated advanced lung cancer.
The global HARMONi trial met its progression-free survival endpoint but did not demonstrate a statistically significant overall survival benefit. Existing Chinese approvals are separate from this US decision.
In Kathmandu, Nepal’s parliamentary leadership requested Chinese support to develop B.P. Koirala Memorial Cancer Hospital into a national cancer research and training institute. New funding and implementation dates remain unconfirmed.
This is a dated video briefing. Reports and availability may have changed since it was recorded; confirm current details before making plans.

